Elanco Animal Health Incorporat (ELAN) Q3 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- $0.27
- Estimate
- $0.20
- Surprise
- +32.8%
- Revenue (period 2026-09-30)
- $1.26B
- Score today
- 5.6/10
Revenue source: xbrl.
How the report landed
Elanco Animal Health Incorporat (ELAN) beat the $0.20 estimate with adjusted EPS of $0.27 — a large 32.8% upside surprise.
Where TrendMatrix's rating stands now
TrendMatrix currently rates ELAN Sell at 5.6/10; no pre/post engine snapshot brackets this report.
4 of the last 4 quarters beat the estimate; this quarter's +32.8% surprise compares with a +21.8% four-quarter average.
What supports the rating
- Sector modifier (Healthcare): +0.5
- Strong earnings beat streak (4/4)
What argues against it
- Analyst target reached - limited upside remaining
- V7 low-quality RISK_OFF penalty: -0.5 (Q=4.6)
- Earnings estimates trending DOWN
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $25.74
- Price target
- $26.30
- Stop
- $23.94
- Upside to target
- +2.2%
- Reward-to-risk
- 0.1:1
Risk check: trading volume is running 2.1× its average — elevated turnover around the report window.
Model outputs from TrendMatrix’s engine as of 2026-11-07 — shown for context, not personalized investment advice.
ELAN at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Drug Manufacturers - Specialty & Generic
- Market cap
- $12.86B
- P/E (fwd)
- 20.2
- 52-week range
- $19.40–$27.98
- Off 52-week high
- 8.0%
- RSI (14)
- 63
- Volume vs avg
- 2.11×
- Score today
- 5.6/10